 |
2 Diseases |  |
12 Trials |
|
12 Trials |  |
490 News |  |
| «123456» |
- || Actemra IV (tocilizumab) / Roche, JW Pharma, Soliris (eculizumab) / AstraZeneca
Review, Journal: Treatment and new evidences in neuromyelitis optica spectrum disorder (Pubmed Central) - Oct 22, 2021
This article discusses off-label azathioprine and mycophenolate mofetil in the treatment of NMOSD and reviews the evidence-based clinical aspects of B/plasma cell depletion, antagonization of IL-6 signaling and blocking the complement pathway...In the recent two years, phase 3 clinical trials provided class I evidence for the efficacy and safety of rituximab (anti-CD20), inebilizumab (anti-CD19), tocilizumab (anti-IL6R), satralizumab (anti-IL6R), and eculizumab (anti-C5) in combination with other immunosuppressants or in monotherapy...Immunosuppression is recommended in NMOSD during pregnancy and lactation, and this should be considered for optimal selection of treatment in fertile female patients. The new monoclonal antibodies broadened treatment options NMOSD, and the treatment strategy of MOGAD has become more straightforward.
- | Soliris (eculizumab) / AstraZeneca
Journal: Neuromyelitis Optica Spectrum Disorders - Present Insights and Recent Developments (Pubmed Central) - Oct 22, 2021
The achievements of the last 15 years have essentially shaped the diagnostic methods and therapy of Neuromyelitis optica spectrum disorders (NMOSD): from discovery of aquaporin 4 antibodies and further development of diagnostic criteria the path has led to the approval of eculizumab and satralizumab as first disease modifying treatments in Europe. This article should give an overview on the present insights and future treatment options.
- || Actemra IV (tocilizumab) / Roche, JW Pharma, Soliris (eculizumab) / AstraZeneca, Enspryng (satralizumab) / Roche
Clinical, Journal: Satralizumab in the treatment of neuromyelitis optica spectrum disorder. (Pubmed Central) - Oct 16, 2021
Here, we review the two randomized, double-blind, Phase III trials that investigated the subcutaneous administration of satralizumab as add-on treatment and monotherapy. Both studies revealed positive effects concerning the reduction of relapse risk for AQP4 seropositive NMOSD patients and generally good tolerability.
- Enspryng (satralizumab) / Roche
[VIRTUAL] Long-Term Safety of Satralizumab in Neuromyelitis Optica Spectrum Disorder: Results from the Open-Label Extension Periods of Sakurasky and Sakurastar () - Oct 8, 2021 - Abstract #CMSC2021CMSC_573;
P3
Both studies revealed positive effects concerning the reduction of relapse risk for AQP4 seropositive NMOSD patients and generally good tolerability. The favourable safety profile of satralizumab was sustained with long-term treatment.
- | Soliris (eculizumab) / AstraZeneca
Journal: Recent advances in the treatment of neuromyelitis optica spectrum disorders. (Pubmed Central) - Sep 29, 2021
The favourable safety profile of satralizumab was sustained with long-term treatment. Eculizumab, inebilizumab, and satralizumab are effective maintenance therapies approved for the treatment of AQP-4 seropositive NMOSD.
- | Enspryng (satralizumab) / Roche
Journal: Satralizumab-mwge. (Pubmed Central) - Sep 23, 2021
Eculizumab, inebilizumab, and satralizumab are effective maintenance therapies approved for the treatment of AQP-4 seropositive NMOSD. No abstract available
- Enspryng (satralizumab) / Roche
[VIRTUAL] SAkuraBONSAI: A prospective, open-label study of satralizumab investigating novel imaging, biomarker, and clinical outcomes in patients with AQP4-IgG seropositive NMOSD (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1581;
P3
This study incorporates comprehensive imaging, biomarker, and clinical assessments in patients with AQP4-IgG+ NMOSD. The data will provide additional evidence for use of satralizumab in NMOSD patient populations where further research is warranted, offering unique insights into potential clinically relevant predictive and prognostic immunologic and imaging markers.
- Enspryng (satralizumab) / Roche
[VIRTUAL] Exploring steroid tapering in NMOSD patients treated with satralizumab in the open-label extension period of SAkuraSky: a case series (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1580;
During the OLE of SAkuraSky, 16 patients tapered steroid and the ARR did not increase from the DBP. Patient numbers limit interpretation.
- Uplizna (inebilizumab) / Horizon Therapeutics, Enspryng (satralizumab) / Roche, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] COVID-19 in neuromyelitis optica spectrum disorder patients in Poland (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1578;
Most of the NMOSD patients under the care of our site had a favourable course of SARS-CoV-2 infection. Continued data collection is needed to increase understanding of SARS-CoV-2 infection impact on the course of NMOSD in patients.
- Enspryng (satralizumab) / Roche
[VIRTUAL] Long-term efficacy of satralizumab in aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD): Results from the open-label extension periods of SAkuraSky and SAkuraStar (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1566;
P3
These long-term results from the SAkura studies demonstrate that the efficacy of satralizumab observed in the DB periods is sustained during the OLE phase. High proportions of patients remained free from relapse, severe relapse, or worsening disease, with a consistently low ARR over more than 3.5 years of treatment.
- Enspryng (satralizumab) / Roche
[VIRTUAL] Long-term safety of satralizumab in neuromyelitis optica spectrum disorder: results from the open-label extension periods of SAkuraSky and SAkuraStar (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1565;
P3
High proportions of patients remained free from relapse, severe relapse, or worsening disease, with a consistently low ARR over more than 3.5 years of treatment. The favourable safety profile of satralizumab was sustained with long-term treatment.
- Enspryng (satralizumab) / Roche
[VIRTUAL] Long-term efficacy of satralizumab in aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD): Results from the open-label extension periods of SAkuraSky and SAkuraStar (Stream 1 Clinical) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1511;
P3
These long-term results from the SAkura studies demonstrate that the efficacy of satralizumab observed in the DB periods is sustained during the OLE phase. High proportions of patients remained free from relapse, severe relapse, or worsening disease, with a consistently low ARR over more than 3.5 years of treatment.
- | Enspryng (satralizumab) / Roche
Journal: Satralizumab for the Treatment of Neuromyelitis Optica Spectrum Disorders. (Pubmed Central) - Sep 8, 2021
High proportions of patients remained free from relapse, severe relapse, or worsening disease, with a consistently low ARR over more than 3.5 years of treatment. Satralizumab appears to be safe and effective as monotherapy or in combination with an immunosuppressant for patients with NMOSD and has the potential to become a valuable treatment option for these patients.
- |||| Enspryng (satralizumab) / Roche
Trial initiation date: A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD) (clinicaltrials.gov) - Aug 18, 2021
P3, N=127, Recruiting, Sponsor: Hoffmann-La Roche
Satralizumab appears to be safe and effective as monotherapy or in combination with an immunosuppressant for patients with NMOSD and has the potential to become a valuable treatment option for these patients. Initiation date: Jul 2021 --> Mar 2021
- | Actemra IV (tocilizumab) / Roche, JW Pharma, Soliris (eculizumab) / Alexion Pharma
Retrospective data, Journal: Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: a Meta-analysis of Randomized Control Trials. (Pubmed Central) - Aug 7, 2021
Compared to the control arm, monoclonal antibody therapy showed a significantly better outcome in restraining the HR for relapse among patients with NMOSD but insignificant effects in NMOSD patients with seronegative APQ4-IgG. The safety profile in each arm had no significant difference.
- Enspryng (satralizumab) / Roche
[VIRTUAL] Satralizumab: a new opportunity for Neuroimmunological disorders (Industry 1) - Aug 6, 2021 - Abstract #WCN2021WCN_829;
The safety profile in each arm had no significant difference. Supported by Roche s.p.a
- Enspryng (satralizumab) / Roche
[VIRTUAL] Satralizumab: a new opportunity for neuroimmunological disorders (Industry 1) - Aug 6, 2021 - Abstract #WCN2021WCN_451;
Supported by Roche s.p.a Supported by Roche s.p.a
- Actemra IV (tocilizumab) / Roche, JW Pharma, Soliris (eculizumab) / AstraZeneca
[VIRTUAL] Current standard of care and new emerging treatments in NMOSD (Stream 7 Educational Sessions) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1401;
Classical immunosuppressive therapies (IST) such as azathioprine, mycophenolate mofetil with and without low-dose oral steroids showed efficacy in non-controlled trials and have been widely used in the past to reduce relapses...Subsequently, after successful clinical trials, three monoclonal antibodies have been approved for the treatment of AQP4-IgG positive NMOSD since 2019: the C5 complement inhibitor eculizumab, the IL-6 receptor antibody satralizumab and the anti-CD19 antibody inebilizumab...IST as well as rituximab and tocilizumab as off-label therapies are usually used for those patients. In light of the new therapeutic landscape the current standard of care in NMOSD is reviewed and treatment recommendations discussed for AQP4-IgG positive and negative NMOSD patients in this educational session.
- Soliris (eculizumab) / AstraZeneca
[VIRTUAL] Indirect comparison analysis of FDA-approved treatment options for adults with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (Stream 7 Therapy / Global views) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_1207;
In light of the new therapeutic landscape the current standard of care in NMOSD is reviewed and treatment recommendations discussed for AQP4-IgG positive and negative NMOSD patients in this educational session. Using available RCT data, NMA results showed that eculizumab monotherapy and eculizumab ± IST demonstrated greater efficacy in prolonging time-to-first relapse when compared with either satralizumab or inebilizumab for treating adults with AQP4-IgG+ NMOSD.
- Enspryng (satralizumab) / Roche
[VIRTUAL] SAkuraBONSAI: A prospective, open-label study of satralizumab investigating novel imaging, biomarker, and clinical outcomes in patients with AQP4-IgG seropositive NMOSD (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_227;
P3
This study incorporates comprehensive imaging, biomarker, and clinical assessments in patients with AQP4-IgG+ NMOSD. The data will provide additional evidence for use of satralizumab in NMOSD patient populations where further research is warranted, offering unique insights into potential clinically relevant predictive and prognostic immunologic and imaging markers.
- Enspryng (satralizumab) / Roche
[VIRTUAL] Exploring steroid tapering in NMOSD patients treated with satralizumab in the open-label extension period of SAkuraSky: a case series (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_226;
During the OLE of SAkuraSky, 16 patients tapered steroid and the ARR did not increase from the DBP. Patient numbers limit interpretation.
- Uplizna (inebilizumab) / Horizon Therapeutics, Enspryng (satralizumab) / Roche, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] COVID-19 in neuromyelitis optica spectrum disorder patients in Poland (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_224;
Most of the NMOSD patients under the care of our site had a favourable course of SARS-CoV-2 infection. Continued data collection is needed to increase understanding of SARS-CoV-2 infection impact on the course of NMOSD in patients.
- Enspryng (satralizumab) / Roche
[VIRTUAL] Long-term efficacy of satralizumab in aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD): Results from the open-label extension periods of SAkuraSky and SAkuraStar (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_212;
P3
These long-term results from the SAkura studies demonstrate that the efficacy of satralizumab observed in the DB periods is sustained during the OLE phase. High proportions of patients remained free from relapse, severe relapse, or worsening disease, with a consistently low ARR over more than 3.5 years of treatment.
- Enspryng (satralizumab) / Roche
[VIRTUAL] Long-term safety of satralizumab in neuromyelitis optica spectrum disorder: results from the open-label extension periods of SAkuraSky and SAkuraStar (ePoster Library) - Aug 3, 2021 - Abstract #ECTRIMS2021ECTRIMS_211;
P3
High proportions of patients remained free from relapse, severe relapse, or worsening disease, with a consistently low ARR over more than 3.5 years of treatment. The favourable safety profile of satralizumab was sustained with long-term treatment.
- |||||||||| Enspryng (satralizumab) / Roche
New P3 trial: A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis (clinicaltrials.gov) - Jul 14, 2021
P3, N=240, Not yet recruiting, Sponsor: Hoffmann-La Roche
- || Enspryng (satralizumab) / Roche
Review, Journal: Satralizumab: First Approval. (Pubmed Central) - Jul 9, 2021
Satralizumab is under regulatory review in the EU and USA, and is undergoing clinical development in several countries worldwide. This article summarizes the milestones in the development of satralizumab leading to this first approval for the treatment of NMOSD.
- || Soliris (eculizumab) / Alexion Pharma
Review, Journal: Immune reconstitution therapy in NMOSD. (Pubmed Central) - Jul 8, 2021
In NMO, control the complement (eculizumab), reconstitute the immune system (AHSCT), transition to immunomodulation (satralizumab) and reserve immunosuppression (inebilizumab) as 4th line. AHSCT might also be used as rescue therapy for severe breakthrough disease after NMO-DMTs.
- ||||| Enspryng (satralizumab) / Roche
European regulatory: #Roche announced that the #EuropeanCommission approved its Enspryng subcutaneous #NMOSDTreatment. MORE HERE: https://t.co/0Fdp5lyttV #Enspryng #Satralizumab #Antibody #Neuromyelitis #NMOSD #ImmunosuppressiveTherapy #Neuroimmunological #Pharma #Biotech @LeviAGarraway @Roche (Twitter) - Jun 29, 2021
- Enspryng (satralizumab) / Roche
[VIRTUAL] Satralizumab in patients with neuromyelitis optica spectrum disorder (NMOSD) and concomitant autoimmune disease (Room Amsterdam) - May 30, 2021 - Abstract #EAN2021EAN_1823;
P3
AHSCT might also be used as rescue therapy for severe breakthrough disease after NMO-DMTs. Satralizumab was well tolerated in NMOSD patients with CAIDs, with comparable safety and efficacy to the overall SAkura study populations.
- Enspryng (satralizumab) / Roche
[VIRTUAL] Satralizumab in adults with AQP4-IgG seropositive NMOSD: Efficacy and safety results from the phase 3 SAkura studies (Room Amsterdam) - May 30, 2021 - Abstract #EAN2021EAN_1822;
P3
Satralizumab was well tolerated in NMOSD patients with CAIDs, with comparable safety and efficacy to the overall SAkura study populations. In AQP4-IgG+ adults with NMOSD, satralizumab significantly reduced relapse risk vs placebo, was well tolerated and showed a favourable safety profile.
- | Soliris (eculizumab) / Alexion Pharma
Journal: Neuromyelitis Optica Spectrum Disorder (Pubmed Central) - May 26, 2021
Currently, there are additional options for therapy with biopharmaceutical agents such as eculizumab, satralizumab, rituximab, or inebilizumab to prevent relapse of the disease. These new options can clearly exceed or surpass the usual treatments and should be considered positively in aggressive cases of NMOSD.
- || Soliris (eculizumab) / Alexion Pharma
Clinical, Review, Journal: Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects. (Pubmed Central) - May 15, 2021
Reserve inebilizumab (immunosuppressant) for breakthrough disease and salvage the severe with AHSCBMT. In NMO, control the complement, transition to modulation, and reserve suppression - and salvage the severe with AHSCBMT.
- || Actemra IV (tocilizumab) / Roche, JW Pharma, Soliris (eculizumab) / Alexion Pharma
Clinical, Review, Journal: Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature. (Pubmed Central) - May 15, 2021
New molecules: Eculizumab, Tocilizumab, Satralizumab are good options for treatment. Drugs like Azathioprine and Mycophenolate are effective, but with a worse risk-benefit ratio, therefore, they are useful alternatives in places that do not have access to monoclonal antibodies.
- || Soliris (eculizumab) / Alexion Pharma
Clinical, Journal: Efficacy and Safety of Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: Evidence from Randomized Controlled Trials. (Pubmed Central) - May 11, 2021
Monoclonal antibody therapy was effective and safe in NMOSD treatment. More RCTs were expected to assess monoclonal antibodies in NMOSD.
- |||||||||| Enspryng (satralizumab) / Roche
New P3 trial: A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with Generalized Myasthenia Gravis (EUDRACT) - Apr 20, 2021
P3, N=240, , Sponsor: F. Hoffmann-La Roche Ltd
- || Soliris (eculizumab) / Alexion Pharma
Review, Journal: Treatment of antibody-mediated encephalomyelitis : Strategies for the treatment of neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease (Pubmed Central) - Apr 10, 2021
More RCTs were expected to assess monoclonal antibodies in NMOSD. Treatment of antibody-mediated encephalomyelitis differs from treatment of multiple sclerosis and requires specific measures.
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Review, Journal: Targeting IL-6 receptor in the treatment of neuromyelitis optica spectrum: a review of emerging treatment options. (Pubmed Central) - Apr 7, 2021
Further, the authors summarize the most recent findings on the use of anti-IL-6R monoclonal antibodies, tocilizumab and satralizumab, in the treatment of NMOSD.Expert opinion: A better understanding of the role of cytokines in NMOSD may provide the neurologist with novel therapies for this disease. IL-6R appears to be a central hub to NMOSD pathogenesis and a relevant therapeutic target.
- || Soliris (eculizumab) / Alexion Pharma
Clinical, Review, Journal: New Therapeutic Landscape in Neuromyelitis Optica. (Pubmed Central) - Apr 7, 2021
Reliable biomarkers to guide therapy decisions are urgently needed. There is a plethora of promising investigational therapies currently in the pipeline with exciting and novel mechanisms of action.
- || Soliris (eculizumab) / Alexion Pharma
Review, Journal: Drug Treatment of Neuromyelitis Optica Spectrum Disorders: Out with the Old, in with the New? (Pubmed Central) - Mar 30, 2021
We are fortunate to have these new drugs available now, but they will not immediately supersede established off-label drugs in this indication. It is still too early to definitively revise the treatment algorithms for NMOSD - although we are probably on the way.
- | Soliris (eculizumab) / Alexion Pharma
Journal: Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders. (Pubmed Central) - Mar 27, 2021
Monoclonal antibodies targeting terminal complement (eculizumab), CD19 (inebilizumab), and the interleukin-6 receptor (satralizumab) have demonstrated efficacy in NMOSD attack prevention in recent phase 3 trials and have gained subsequent regulatory approval in the USA and other countries. We aim to review the evidence supporting the efficacy of these new drugs.
- | Enspryng (satralizumab) / Roche
Journal: Satralizumab: an interleukin-6 (IL-6) receptor antagonist for the treatment of neuromyelitis optica spectrum disorders. (Pubmed Central) - Mar 24, 2021
Two recent phase III studies have demonstrated that satralizumab significantly reduced the relapse rate in NMOSD by 76-79%. This beneficial effect was apparently confined to patients who have anti-AQP4 antibodies and satralizumab did not reduce the rate of pain or fatigue in NMOSD patients.
- || Actemra IV (tocilizumab) / Roche, JW Pharma, Soliris (eculizumab) / Alexion Pharma
Review, Journal: Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder. (Pubmed Central) - Mar 23, 2021
These trials support the efficacy of rituximab and tocilizumab and led to the FDA approval of eculizumab, satralizumab and inebilizumab for NMOSD. Our review provides an update on these evidence-based disease-modifying therapies and discussed the treatment of acute relapses in NMOSD.
- Enspryng (satralizumab) / Roche
[VIRTUAL] Satralizumab in Patients with Neuromyelitis Optica Spectrum Disorder and Concomitant Autoimmune Disease () - Mar 18, 2021 - Abstract #AAN2021AAN_244;
P3
Our review provides an update on these evidence-based disease-modifying therapies and discussed the treatment of acute relapses in NMOSD. Satralizumab was well tolerated in NMOSD patients with CAIDs, with comparable safety and efficacy to the overall SAkura study populations.
- |||| Enspryng (satralizumab) / Roche
Enrollment open: A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD) (clinicaltrials.gov) - Mar 16, 2021
P3, N=127, Recruiting, Sponsor: Hoffmann-La Roche
Satralizumab was well tolerated in NMOSD patients with CAIDs, with comparable safety and efficacy to the overall SAkura study populations. Not yet recruiting --> Recruiting
- Enspryng (satralizumab) / Roche
[VIRTUAL] Efficacy and safety of satralizumab in adults with AQP4IgG seropositive neuromyelitis optica spectrum disorder (NMOSD): Results from the phase 3 SAkura studies () - Mar 6, 2021 - Abstract #ACTRIMSForum2021ACTRIMS_Forum_317;
P3
Satralizumab significantly reduced relapse risk vs placebo in AQP4-IgG+ adults when used as a monotherapy or in combination with IST. Satralizumab was well tolerated and showed a favourable safety profile.
- | Soliris (eculizumab) / Alexion Pharma
Journal: Current and Emerging Biologics for the Treatment of Neuromyelitis Optica Spectrum Disorders. (Pubmed Central) - Feb 23, 2021
The interleukin-6 receptor inhibitor satralizumab and anti-CD19 antibody inebilizumab have published positive phase III trial results and await approval in the near future...Although we will have even more evidence-based therapy options in the future, empirically used medications will keep their importance for now. The potential effect of new medications in AQP4 antibody seronegative NMOSD and patients with an NMOSD phenotype and antibodies to myelin oligodendrocyte glycoprotein (MOG) remains to be determined.
- | Soliris (eculizumab) / Alexion Pharma, Ultomiris IV (ravulizumab IV) / Alexion Pharma
Journal: Emerging drugs for the treatment of neuromyelitis optica. (Pubmed Central) - Feb 4, 2021
For the first time in this disease, class I treatment evidence is available, but long-term data will be necessary to confirm the overall promising study results of the compounds close to approval. While drug development still centers around AQP4 antibody seropositive patients, current and future research requires consideration of possible diverging treatment demands for the smaller group of seronegative patients and patients with presence of MOG antibodies.
- | Soliris (eculizumab) / Alexion Pharma
Journal: Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases. (Pubmed Central) - Jan 29, 2021
While drug development still centers around AQP4 antibody seropositive patients, current and future research requires consideration of possible diverging treatment demands for the smaller group of seronegative patients and patients with presence of MOG antibodies. New insights into pathological mechanisms and therapeutic responses argue to consider NMOSD with AQP4-IgG and MOGAD as separate brain disease entities.
- || Soliris (eculizumab) / Alexion Pharma
Review, Journal: New therapies for neuromyelitis optica spectrum disorder. (Pubmed Central) - Jan 29, 2021
WHERE NEXT?: Despite the rarity of neuromyelitis optica spectrum disorder, a relative abundance of preventive treatment options now exists. In the future, trials should focus on areas of unmet need, including aquaporin-4 seronegative disease, and on development of treatments for acute relapses and for recovery from autoimmune attacks in the CNS.
- Soliris (eculizumab) / Alexion Pharma
[VIRTUAL] NMO and antiMOG: Updates on Diagnosis and Treatment (Scientific Program Auditorium) - Jan 27, 2021 - Abstract #ACTRIMSForum2021ACTRIMS_Forum_79;
The availability of proven attack prevention biologics for NMOSD provides new hope for patients with NMOSD. Improved understanding of MOGAD phenotype, natural history and immunopathologic mechanisms of disease combined with optimized MOG-IgG detection assays will allow development of international diagnostic criteria and assist in drug trial design.